Stockreport

CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study [Yahoo! Finance]

Cardiff Oncology, Inc.  (CRDF) 
PDF candidate, onvansertib (20 mg and 30 mg), in combination with standard-of-care (SOC) chemotherapy to treat first-line RAS-mutated metastatic colorectal cancer (mCRC) pat [Read more]